A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante  1     Valerie Pivorunas  2     James Butler  3     Naim Mahi  3     Nael M. Mostafa  3     Melanie Ruzek  2     James Fann  2     Feng Hong  4     Xiaohong Cao     Nizar Smaoui     Justin Wade Davis     Jasmina Kalabic     Alexandra Song     Heath M. Guay     Florian Rieder     Julian Panés     Jean-Frédéric Colombel    
1 University Hospitals Leuven,KU Leuven,Belgium
2 AbbVie Bioresearch Center,Worcester,United States
3 AbbVie Inc.,North Chicago,United States
4 AbbVie Bior

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing